ArticleRSC advances2019
Encapsulation of echinomycin in cyclodextrin inclusion complexes into liposomes:
Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 62 citations in OpenAlex.
- Synergistic antimicrobial nanocomposite: Protamine-loaded PVP-capped silver nanoparticles for combating multidrug-resistant infections.Asian journal of pharmaceutical sciences · 2026Article
- Improved Encapsulation and Potential of Liposomal Tosufloxacin via Inclusion in Cyclodextrin.AAPS PharmSciTech · 2025Article
- Remote Co-Loading of Doxorubicin and Hydralazine into PEGylated Liposomes: In Vitro Anti-Proliferative Effect Against Breast Cancer.Molecules (Basel, Switzerland) · 2025Article
- Formation and evaluation of doxorubicin and cromoglycate metal-organic framework for anti-cancer activity.Nanomedicine (London, England) · 2025Article
- In vitro cellular interaction of drug-loaded liposomes with 2D and 3D cell culture of U87-MG cell line.PloS one · 2025Article
- Optimized Rutin-incorporating PEGylated Nanoliposomes as a Model with Remarkable Selectivity Against PANC1 and MCF7 Cell Lines.Anti-cancer agents in medicinal chemistry · 2025Article
- Green synthesizedFuture science OA · 2024Article
- Metal-organic frameworks as nanoplatforms for combination therapy in cancer treatment.Medical oncology (Northwood, London, England) · 2024Review
- Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy.Biomolecules & therapeutics · 2024Review
- Liposome-Based Drug Delivery Systems in Cancer Research: An Analysis of Global Landscape Efforts and Achievements.Pharmaceutics · 2024Article
- Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Anti-Obesity Drug Delivery Systems: Recent Progress and Challenges.Pharmaceutics · 2023Review
- Article
- The pathogenesis and regulatory role of HIF-1 in rheumatoid arthritis.Central-European journal of immunology · 2023Review
- Review
- Cinnamaldehyde-cucurbituril complex: investigation of loading efficiency and its role in enhancing cinnamaldehydeRSC advances · 2022Article
- Characterization of Streptomyces sp. LS462 with high productivity of echinomycin, a potent antituberculosis and synergistic antifungal antibiotic.Journal of industrial microbiology & biotechnology · 2021Article
- Preparation, Characterization, and Anticancer Effects of Capsaicin-Loaded Nanoliposomes.Nutrients · 2021Article
- Lipid nanostructures for targeting brain cancer.Heliyon · 2021Review
- Aptamer-functionalized pH-sensitive liposomes for a selective delivery of echinomycin into cancer cells.RSC advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Echinomycin, a DNA bis-intercalator peptide, belongs to the family of quinoxaline antibiotics. Echinomycin exhibits potent antitumor and antimicrobial activity. However, it is highly water insoluble and suffers from low bioavailability and unwanted side effects. Therefore, developing new formulations and delivery systems that can enhance echinomycin solubility and therapeutic potency is needed for further clinical application. In this study, echinomycin has been complexed into the hydrophobic cavity of γ-cyclodextrin (γCD) then encapsulated into PEGylated liposomes. The anti-proliferative and anti-invasive effect has been evaluated against U-87 MG glioblastoma cells. Echinomycin-in-γCD inclusion complexes have been characterized by phase solubility assay, TLC, and
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.